Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: Current role and future perspectives

Cancer Treatment Reviews

Volumn 37, Issue 3, 2011, Pages 208-211

  Mastro, Lucia Del ^a   Levaggi, Alessia ^a   Giraudi, Sara ^a   Pronzato, Paolo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Adjuvant therapy; Early breast cancer; Endocrine therapy; Infertility; LH RH agonists; Ovarian ablation

Indexed keywords

ESTRADIOL; GONADORELIN AGONIST; GOSERELIN; LUTEINIZING HORMONE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER PATIENT; DOWN REGULATION; HORMONAL THERAPY; HUMAN; OVARY FUNCTION; PREMENOPAUSE; REVIEW;

AGE OF ONSET; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; PREMENOPAUSE;

EID: 79952004670     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.07.007     Document Type: Review

References (27)

1. Li C.L., Daling J.R., Malone K.E., et al. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003, 21:28-34.
2. Soreide J.A., Varhaug J.E., Fjosna H.E., et al. Adjuvant endocrine treatment (goserelin vs tamoxifen) in premenopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. Eur J Surg Oncol 2002, 28:505-510.
3. Mitsuyama S., Nomura Y., Ohno S., et al. Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-Zoladex Breast Cancer Study Group Trial B (Japanese). Jpn J Cancer Chemother 2005, 32:2071-2077.
4. Hackshaw A., Baum M., Fornander T., et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 2009, 101:341-349.
5. Cuzick J., Ambroisine L., Davidson N., et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369:1711-1723.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. An overview of the randomized trials. Lancet 2005;365:1687-1717.
7. Klijn J.G., Beex L.V., Mauriac L., et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000, 92:903-911.
8. Davidson N.E., O'Nell A.M., Vukov A.M., et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive steroid hormone receptor-positive breast cancer. Results from INT 0101 (E5188). J Clin Oncol 2005, 23:5973-5982.
9. Forward D.P., Cheung K.L., Jackson L., et al. Clinical and endocrine data for goserelin plus anastrozole as second line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004, 90(3):590-594.
10. Rossi E., Morabito A., De Maio E., et al. Endocrine effects of adjuvant letrozole+triptorelin compared with tamoxifen+triptorelin in premenopausal patients with early breast cancer. J Clin Oncol 2008, 26(2):264-270.
11. Park I.H., Ro J., Lee K.S., et al. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol 2010, 28:2705-2711.
12. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zolendronic acid in premenopausal breast cancer. N Engl J Med 2009, 360(7):679-691.
13. International Bresat Cancer Study Group (IBCSG). Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003;95(24):1833-46.
14. Schmid P., Untch M., Kossè V., et al. Leuproline acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol 2007, 25:2509-2515.
15. Smith I.E., Dowsett M., Yap Y.S., et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhea: caution and suggested guidelines. J Clin Oncol 2006, 24:2444-2447.
16. National Cancer Institute Clinical Trials. NCT00917969; NCT00066690; NCT00066703. http://www.clinicaltrials.gov.
17. Rivkees A.S., Crawford J.D. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988, 259:2123-2125.
18. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to preservation of embryo, oocytes, or ovaries. Oncologist 2007, 12(9):1044-1054.
19. Beck-Fruchter R., Weiss A., Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 2008, 14(6):553-561.
20. Fox K.R., Scialla J., Moore H. Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer. Proc Am Soc Clin Oncol 2003, 22:13. [abstr 50].
21. Recchia F., Sica G., De Filippis S., et al. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Dugs 2002, 13:417-424.
22. Urriticoechea A., Walsh G., Rigg A., et al. Ovarian function protection with goserelin during adjuvant chemotherapy in pre-menopausal women with early breast cancer. Breast Cancer Res Treat 2004, 88(Suppl. 1):S229. [abstr 6028].
23. Del Mastro L., Catzeddu T., Boni L., et al. Prevention of chemotherapy induced menopause by temporary ovarian suppression with goserelin in young early breast cancer patients. Ann Oncol 2006, 17:74-78.
24. Badawy A., Elnashar A., El-Ashry M., et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009, 91(3):694-697.
25. Gerber B., Stehle H., Ricardo F., et al. ZORO: a prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). J Clin Oncol 2009, 27:526.
26. Leonard R.C., Adamson D., Anderson R., et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 2010, 28(Suppl.):15s. [abstr 590].
27. Del Mastro L., Boni L., Michelotti A., et al. Role of luteinizing hormone-releasing hormone analog (LH-Rha) triptorelin in preserving ovarian function during chemotherapy for early breast cancer patients: results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. J Clin Oncol 2010, 28(Suppl.):15s. [abstr 528].